Screening strategy versus drug efficacy: Revisiting the evidence for vaginal progesterone in short cervix

Jeremy Boujenah, Patrick Rozenberg · 2026

Read Screening strategy versus drug efficacy: Revisiting the evidence for vaginal progesterone in short cervix by Jeremy Boujenah, Patrick Rozenberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427669.txt.

Description

Boujenah and Rozenberg wrote in 2026 to dispute a review's verdict that evidence is too weak to back universal cervix screening with vaginal progesterone to prevent preterm birth. Their charge is that the review blends two separate questions: whether screening whole populations helps, and whether the drug works in women already found to have a short cervix.

The trials behind the verdict compared screening against no screening, and fewer than three in a hundred women in them ever received the drug, which dilutes any effect toward zero. Trials that gave progesterone to women with a short cervix did show benefit. The letter also notes that screening trials used looser length cut-offs, enrolling lower-risk women. Weighing biology, pooled patient-level analyses, and the drug's low risk and cost, the authors argue for offering the strategy now.

Catalog record

CREATORJeremy Boujenah, Patrick Rozenberg
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE4 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13427669

Browse the full library · About the Tower of Babel